temozolomide has been researched along with veliparib in 47 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (17.02) | 29.6817 |
| 2010's | 32 (68.09) | 24.3611 |
| 2020's | 7 (14.89) | 2.80 |
| Authors | Studies |
|---|---|
| Bontcheva-Diaz, V; Bouska, JJ; Donawho, CK; Frost, DJ; Gandhi, VB; Giranda, VL; Gong, J; Johnson, EF; Klinghofer, V; Liu, X; Luo, Y; Marsh, KC; Olson, AM; Osterling, DJ; Penning, TD; Shi, Y; Zhu, GD | 1 |
| Bouska, JJ; Donawho, CK; Ellis, PA; Frost, DJ; Giranda, VL; Johnson, EF; Leverson, J; Liu, X; Luo, Y; Marcotte, PA; Olson, AM; Osterling, DJ; Penning, TD; Przytulinska, M; Rodriguez, LE; Shi, Y; Soni, N; Stavropoulos, J; Thomas, S; Tong, Y | 1 |
| Artali, R; Barbarino, M; Battistuzzi, G; Carollo, V; Dallavalle, S; De Paolis, F; Gallo, G; Giannini, G; Guglielmi, MB; Milazzo, FM; Vesci, L | 1 |
| Borghi, D; Busel, AA; Caprera, F; Casale, E; Ciomei, M; Cirla, A; Corti, E; D'Anello, M; Donati, D; Fasolini, M; Felder, ER; Forte, B; Galvani, A; Isacchi, A; Khvat, A; Krasavin, MY; Lupi, R; Montagnoli, A; Orsini, P; Papeo, G; Perego, R; Pesenti, E; Pezzetta, D; Posteri, H; Rainoldi, S; Riccardi-Sirtori, F; Scolaro, A; Sola, F; Zuccotto, F | 1 |
| Cao, R; Chen, X; Ji, M; Xu, B; Zhou, J; Zhu, Z | 1 |
| Feng, Y; Gao, Y; Gong, W; Guo, Y; Huo, CX; Jiang, B; Kuang, X; Liu, X; Liu, Y; Luo, L; Lv, L; Peng, H; Qi, R; Qin, Z; Qiu, M; Ren, B; Su, D; Sun, X; Tang, T; Wang, F; Wang, H; Wang, L; Wang, X; Wang, Z; Wei, M; Wu, Y; Xu, D; Xu, H; Yan, H; Yu, F; Zhao, Y; Zhou, C; Zhu, Y | 1 |
| Colon-Lopez, M; Donawho, C; Ellis, PA; Frost, DJ; Giranda, VL; Kinders, R; LeBlond, D; Lin, CT; Liu, X; Luo, Y; Palma, J; Rodriguez, LE; Saltarelli, M; Shi, Y | 1 |
| Colon-Lopez, M; Cox, BF; Donawho, C; Frost, D; Ghoreishi-Haack, N; Giranda, VL; Guan, R; Hradil, VP; Jarvis, K; Johnson, EF; Klinghofer, V; Liu, X; Luo, Y; Palma, J; Penning, T; Rodriguez, LE; Rosenberg, SH; Shi, Y; Zhu, GD | 1 |
| Carlson, BL; Clarke, MJ; Curtin, NJ; Decker, PA; Grogan, PT; Lou, Z; Mladek, AC; Mulligan, EA; Plummer, ER; Sarkaria, JN; Schroeder, MA; Wu, W | 1 |
| Berg, SL; Bertuch, AA; Blaney, SM; Delaney, SL; Dolan, ME; Hegde, M; Horton, TM; Jenkins, G; Pati, D; Ribes-Zamora, A; Zhang, L | 1 |
| Anderson, M; Giranda, VL; Han, EK; Johnson, EF; Lasko, L; Leverson, J; Liu, X; Luo, Y; McGonigal, T; Palma, J; Penning, T; Roberts, L; Rosenberg, S; Semizarov, D; Shi, Y; Shoemaker, AR; Wang, G; Zhu, GD | 1 |
| Bukofzer, G; Donawho, CK; Ellis, PA; Frost, DJ; Giranda, VL; Lasko, L; Liu, X; Montgomery, D; Niquette, A; Palma, JP; Penning, TD; Rodriguez, LE; Rosenberg, SH; Shi, Y; Wang, YC; Zhu, GD | 1 |
| Bachoo, RM; Burma, S; Camacho, CV; Hahm, B; McEllin, B; Mukherjee, B; Tomimatsu, N | 1 |
| Donawho, CK; Ellis, PA; Harlan, JE; Iyer, R; Johnson, EF; Ladror, US; Liu, X; Maag, DX; Palma, JP; Patterson, MJ; Penning, TD; Ready, DB; Shi, Y; Shoemaker, AR; Solomon, LR; Soni, NB; Surber, BW; Xu, AJ | 1 |
| Gu, F; Li, WL; Sun, ZF | 1 |
| Barazzuol, L; Burnet, NG; Jena, R; Jeynes, JC; Kirkby, KJ; Kirkby, NF; Meira, LB | 1 |
| Beijnen, JH; Beumer, JH; Buil, LC; Christner, SM; de Gooijer, MC; Lin, F; Roig, EM; van Tellingen, O; Würdinger, T | 1 |
| Doroshow, JH; Ji, J; Morris, J; Murai, J; Pommier, Y; Takeda, S; Zhang, Y | 1 |
| Alumkal, JJ; Carducci, MA; Cetnar, J; Chyla, B; Giranda, VL; Hussain, M; McKeegan, EM; Qian, J; Refici-Buhr, M; Shepherd, SP; Slovin, S | 1 |
| Barrientos, A; Carazo, Á; Delgado, Á; López Viota, J; Muñoz-de-Rueda, P; Muñoz-Gámez, JA; Quiles-Perez, R; Ruiz-Extremera, Á; Salmerón, J; Sanjuán-Nuñez, L | 1 |
| Bakken, KK; Boakye-Agyeman, F; Carlson, BL; Gupta, SK; Kizilbash, SH; Mladek, AC; Reid, J; Sarkaria, JN; Schroeder, MA | 1 |
| Adesina, A; Blaney, SM; Boyett, J; Chen, A; Chyla, B; Fouladi, M; Giranda, V; Goldman, S; Kilburn, L; Kocak, M; Kun, L; Li, XN; McKeegan, E; Onar-Thomas, A; Pollack, IF; Su, JM; Thompson, P; Warren, KE | 1 |
| Bahrami, A; Benavente, C; Bradley, C; Calabrese, C; Caufield, W; Dyer, MA; Freeman, BB; Gordon, B; Goshorn, R; Griffiths, LM; Hatfield, MJ; Karlström, Å; Loh, A; Miller, GM; Pappo, A; Potter, PM; Sablauer, A; Shelat, AA; Shirinifard, A; Snyder, SE; Stewart, E; Thiagarajan, S; Tsurkan, L; Twarog, NR; Wu, J | 1 |
| Balvers, RK; Berghauser Pont, LM; Dirven, CM; Kleijn, A; Kloezeman, JJ; Lamfers, ML; Leenstra, S | 1 |
| Chyla, B; Daud, A; Falotico, N; Friedlander, P; Giranda, VL; Hamid, O; Jiang, F; Luo, Y; McArthur, GA; McKee, M; McKeegan, E; Middleton, MR; Mostafa, NM; Plummer, R; Qian, J; Zhu, M | 1 |
| Dorsch-Vogel, K; Gabrielson, A; He, AR; Jha, R; Marshall, JL; Pishvaian, MJ; Smaglo, B; Tesfaye, AA; Wang, H | 1 |
| Cavaliere, R; Chakravarti, A; Chmura, SJ; Colman, H; de Groot, JF; Gilbert, MR; Grimm, SA; Kee, AY; Kesari, S; Krauze, A; Lieberman, FS; Mehta, M; Mohile, N; Robins, HI; Trotti, AM; Wang, F; Zhang, P | 1 |
| Bakken, KK; Ballman, KV; Boakye-Agyeman, F; Carlson, BL; Cen, L; Decker, PA; Eckel-Passow, JE; Gupta, SK; Jenkins, RB; Kitange, GJ; Kizilbash, SH; Mladek, AC; Pokorny, JL; Reid, JM; Sarkar, G; Sarkaria, JN; Schroeder, MA; Sulman, EP; Verhaak, RG | 1 |
| Chenevert, TL; Galbán, CJ; Galbán, S; Heist, KA; Holland, EC; Lemasson, B; Li, Y; Rehemtulla, A; Ross, BD; Tsein, C; Wang, H; Zhu, Y | 1 |
| de Stanchina, E; Desmeules, P; Gardner, EE; Lok, BH; Ni, A; Poirier, JT; Powell, SN; Rekhtman, N; Riaz, N; Rudin, CM; Schneeberger, VE; Teicher, BA | 1 |
| Diéras, V; Domchek, SM; Friedlander, M; Garber, JE; Giranda, VL; Han, HS; Isakoff, SJ; Johnson, EF; Kaufman, B; Maag, D; Puhalla, S; Qin, Q; Robson, M; Shepherd, SP; Telli, ML | 1 |
| Giranda, V; Munasinghe, W; Nuthalapati, S; Xiong, H | 1 |
| Bondarenko, I; Campone, M; Chmielowska, E; Citrin, D; Diéras, V; Domchek, SM; Friedlander, M; Garber, JE; Gradishar, W; Han, HS; Isakoff, SJ; Jager, A; Jakobsen, EH; Kaklamani, V; Kaufman, B; Marcom, PK; Nickner, C; Palácová, M; Puhalla, S; Qian, J; Qin, Q; Ratajczak, CK; Robson, M; Shepherd, SP; Shparyk, Y; Telli, ML | 1 |
| Tutt, A | 1 |
| Bensman, Y; Byers, LA; Cardnell, RJ; Chen, A; Chiappori, A; de Groot, P; Diao, L; Dowlati, A; Fleisher, M; Fujimoto, J; Hann, CL; Heymach, JV; Hurtado, B; Kris, MG; Krug, LM; Long, L; Owonikoko, TK; Pietanza, MC; Rudin, CM; Sulman, EP; Wang, J; Waqar, SN; Wistuba, II; Woo, KM | 1 |
| Sidaway, P | 1 |
| Bering, EA; Blough, MD; Bohm, AK; Bukhari, S; Cabral, M; Cahill, DP; Cairncross, JG; Chan, JA; Ezhilarasan, R; Gerber, A; Goodman, LD; Kaplan, DR; Kaufmann, AB; Lun, X; Marra, M; Mason, W; Maxwell, L; Pedersen, H; Ricks, CB; Robbins, SM; Safdar, S; Sayeed, W; Senger, DL; Shen, Y; Sulman, EP; Yuan, AL | 1 |
| Beumer, JH; Chen, A; Gobburu, J; Gojo, I; Gopalakrishnan, M; Greer, JM; Karp, JE; Kiesel, BF; Mehrotra, S; Piekarz, R; Rudek, MA; Singh, R | 1 |
| Liang, F | 1 |
| Byers, LA; Diao, L; Pietanza, MC; Wang, J | 1 |
| Adesina, A; Ansell, P; Baxter, PA; Billups, CA; Blaney, SM; Broniscer, A; Dunkel, IJ; Fouladi, M; Giranda, V; Kilburn, L; Li, XN; Onar-Thomas, A; Paulino, A; Poussaint, TY; Quaddoumi, I; Smith, ER; Su, JM; Thompson, P | 1 |
| Baxter, P; Billups, C; Brown, D; Dunkel, IJ; Fangusaro, JR; Law, M; Onar-Thomas, A; Patay, Z; Poussaint, TY; Shiroishi, MS; Vajapeyam, S; Vezina, G | 1 |
| Chen, AP; Das, B; Doroshow, JH; Foster, JC; Karlovich, C; Konaté, MM; Kummar, S; Leong, S; Li, MC; Lih, CJ; Meric-Bernstam, F; Moore, N; O'Sullivan Coyne, G; Palmisano, A; Piekarz, R; Polley, E; Raghav, KPS; Rosenberger, CL; Rubinstein, LV; Simon, R; Simpson, M; Sims, D; Waqar, S; Williams, PM; Zhao, Y | 1 |
| Ashley, DM; Back, M; Barnes, EH; Buckland, ME; Fisher, L; Foote, MC; Hall, M; Khasraw, M; Koh, ES; Leonard, R; Lwin, Z; McDonald, KL; Rosenthal, M; Sim, HW; Simes, J; Sulman, EP; Wheeler, H; Yip, S | 1 |
| Chabner, BA; Ellisen, LW; Garber, JE; Gelman, RS; Goss, PE; Habin, K; Isakoff, SJ; Keenan, TE; Overmoyer, B; Tung, NM; Winer, EP; Xu, J; Yeap, BY | 1 |
| Al-Ansari, S; Bronckers, ALJJ; Brook, AH; de Lange, J; Jalali, R; Nadjmi, N; Raber-Durlacher, J; Rozema, FR; van Tellingen, O | 1 |
16 trial(s) available for temozolomide and veliparib
| Article | Year |
|---|---|
Veliparib plus temozolomide in metastatic melanoma trends toward increased PFS but results are not statistically significant.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Dacarbazine; Disease-Free Survival; Double-Blind Method; Humans; Melanoma; Neoplasm Staging; Temozolomide | 2011 |
Targeting DNA repair with combination veliparib (ABT-888) and temozolomide in patients with metastatic castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Dacarbazine; DNA Repair; Humans; Kallikreins; Male; Middle Aged; Pilot Projects; Poly(ADP-ribose) Polymerase Inhibitors; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Temozolomide; Treatment Outcome | 2014 |
A phase I trial of veliparib (ABT-888) and temozolomide in children with recurrent CNS tumors: a pediatric brain tumor consortium report.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Benzimidazoles; Brain Neoplasms; Child; Child, Preschool; Dacarbazine; Female; Humans; Infant; Leukocytes, Mononuclear; Male; Maximum Tolerated Dose; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Temozolomide; Young Adult | 2014 |
Randomized phase II study evaluating veliparib (ABT-888) with temozolomide in patients with metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Benzimidazoles; Brain Neoplasms; Dacarbazine; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Poly(ADP-ribose) Polymerase Inhibitors; Prognosis; Survival Rate; Temozolomide; Young Adult | 2015 |
Phase II study of temozolomide and veliparib combination therapy for sorafenib-refractory advanced hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carcinoma, Hepatocellular; Dacarbazine; Disease-Free Survival; DNA Methylation; DNA Repair; DNA, Neoplasm; Drug Resistance, Neoplasm; Fatigue; Female; Genes, BRCA1; Genes, BRCA2; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Poly(ADP-ribose) Polymerase Inhibitors; Salvage Therapy; Sorafenib; Temozolomide; Treatment Failure | 2015 |
A randomized phase I/II study of ABT-888 in combination with temozolomide in recurrent temozolomide resistant glioblastoma: an NRG oncology RTOG group study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Benzimidazoles; Bevacizumab; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Drug Resistance, Neoplasm; Drug Therapy, Combination; Female; Glioblastoma; Humans; Male; Middle Aged; Poly(ADP-ribose) Polymerase Inhibitors; Survival Analysis; Temozolomide; Treatment Outcome; Young Adult | 2016 |
A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; BRCA1 Protein; BRCA2 Protein; Breast Neoplasms; Carboplatin; Clinical Protocols; Dacarbazine; Drug Monitoring; Female; Humans; Models, Statistical; Paclitaxel; Research Design; Sample Size; Temozolomide | 2017 |
Clinical Pharmacokinetics and Mass Balance of Veliparib in Combination with Temozolomide in Subjects with Nonhematologic Malignancies.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Benzimidazoles; Biological Availability; Dose-Response Relationship, Drug; Drug Interactions; Female; Humans; Male; Middle Aged; Neoplasms; Temozolomide | 2018 |
Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Breast Neoplasms, Male; Carboplatin; Female; Genes, BRCA1; Genes, BRCA2; Germ-Line Mutation; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Placebos; Single-Blind Method; Temozolomide; Young Adult | 2018 |
Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Biomarkers, Tumor; DNA Methylation; DNA Modification Methylases; DNA Mutational Analysis; DNA Repair Enzymes; Double-Blind Method; Female; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Neoplastic Cells, Circulating; Nuclear Proteins; Placebos; Poly (ADP-Ribose) Polymerase-1; Promoter Regions, Genetic; Small Cell Lung Carcinoma; Temozolomide; Tumor Suppressor Proteins | 2018 |
Population pharmacokinetics and exposure-response assessment of veliparib co-administered with temozolomide in patients with myeloid leukemias.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Incidence; Leukemia, Myeloid, Acute; Male; Maryland; Middle Aged; Models, Statistical; Mucositis; Poly(ADP-ribose) Polymerase Inhibitors; Prognosis; Temozolomide; Tissue Distribution; Young Adult | 2019 |
A phase I/II study of veliparib (ABT-888) with radiation and temozolomide in newly diagnosed diffuse pontine glioma: a Pediatric Brain Tumor Consortium study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Brain Neoplasms; Brain Stem Neoplasms; Child; Glioma; Humans; Temozolomide | 2020 |
Advanced ADC Histogram, Perfusion, and Permeability Metrics Show an Association with Survival and Pseudoprogression in Newly Diagnosed Diffuse Intrinsic Pontine Glioma: A Report from the Pediatric Brain Tumor Consortium.
Topics: Adolescent; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Benchmarking; Benzimidazoles; Brain Stem Neoplasms; Chemoradiotherapy; Child; Diffuse Intrinsic Pontine Glioma; Disease Progression; Female; Humans; Image Interpretation, Computer-Assisted; Magnetic Resonance Imaging; Male; Neuroimaging; Perfusion Imaging; Prognosis; Retrospective Studies; Survival Analysis; Temozolomide | 2020 |
Molecular Profiling-Based Assignment of Cancer Therapy (NCI-MPACT): A Randomized Multicenter Phase II Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzimidazoles; Carboplatin; DNA, Neoplasm; Double-Blind Method; Everolimus; Female; Gene Expression Profiling; Humans; Male; Middle Aged; Molecular Diagnostic Techniques; Neoplasms; Pyrazoles; Pyridones; Pyrimidinones; Temozolomide; Young Adult | 2021 |
A randomized phase II trial of veliparib, radiotherapy, and temozolomide in patients with unmethylated MGMT glioblastoma: the VERTU study.
Topics: Antineoplastic Agents, Alkylating; Benzimidazoles; Brain Neoplasms; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Glioblastoma; Humans; Male; Middle Aged; Radiation Oncology; Temozolomide; Tumor Suppressor Proteins | 2021 |
Phase II trial of veliparib and temozolomide in metastatic breast cancer patients with and without BRCA1/2 mutations.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; BRCA1 Protein; Breast Neoplasms; Carboplatin; Female; Germ-Line Mutation; Humans; Mutation; Temozolomide | 2021 |
31 other study(ies) available for temozolomide and veliparib
| Article | Year |
|---|---|
Discovery of the Poly(ADP-ribose) polymerase (PARP) inhibitor 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide (ABT-888) for the treatment of cancer.
Topics: Animals; Antineoplastic Agents; Area Under Curve; Benzimidazoles; Biological Availability; Carboplatin; Cyclophosphamide; Dacarbazine; Dogs; Enzyme Inhibitors; Female; Haplorhini; Humans; Magnetic Resonance Spectroscopy; Melanoma, Experimental; Mice; Mice, SCID; Poly(ADP-ribose) Polymerase Inhibitors; Rats; Temozolomide | 2009 |
Synthesis and evaluation of a new generation of orally efficacious benzimidazole-based poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors as anticancer agents.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Benzimidazoles; Biological Availability; Cell Line, Tumor; Dacarbazine; Drug Synergism; Female; Humans; Male; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Neoplasm Transplantation; Oxadiazoles; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Pyridines; Structure-Activity Relationship; Temozolomide; Transplantation, Heterologous | 2009 |
Novel PARP-1 inhibitors based on a 2-propanoyl-3H-quinazolin-4-one scaffold.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Enzyme Inhibitors; Female; Humans; Mice; Mice, SCID; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Quinazolinones; Structure-Activity Relationship; Xenograft Model Antitumor Assays | 2014 |
Discovery of 2-[1-(4,4-Difluorocyclohexyl)piperidin-4-yl]-6-fluoro-3-oxo-2,3-dihydro-1H-isoindole-4-carboxamide (NMS-P118): A Potent, Orally Available, and Highly Selective PARP-1 Inhibitor for Cancer Therapy.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biological Availability; Cell Proliferation; Dacarbazine; Drug Screening Assays, Antitumor; Female; Heterografts; High-Throughput Screening Assays; Humans; Isoindoles; Mice, Inbred BALB C; Mice, Nude; Microsomes, Liver; Models, Molecular; Neoplasm Transplantation; Pancreatic Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Rats, Sprague-Dawley; Structure-Activity Relationship; Temozolomide; Triple Negative Breast Neoplasms | 2015 |
Discovery of 2-substituted 1H-benzo[d]immidazole-4-carboxamide derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors with in vivo anti-tumor activity.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Cell Line; Crystallography, X-Ray; Dacarbazine; Drug Design; Drug Synergism; Enzyme Inhibitors; Heterografts; Inhibitory Concentration 50; Poly (ADP-Ribose) Polymerase-1; Protein Binding; Structure-Activity Relationship; Temozolomide | 2017 |
Discovery of Pamiparib (BGB-290), a Potent and Selective Poly (ADP-ribose) Polymerase (PARP) Inhibitor in Clinical Development.
Topics: Animals; Binding Sites; Carbazoles; Cell Proliferation; Dogs; Female; Fluorenes; Half-Life; Humans; Indoles; Isoenzymes; Mice; Microsomes; Molecular Docking Simulation; Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Rats; Structure-Activity Relationship; Xenograft Model Antitumor Assays | 2020 |
An enzyme-linked immunosorbent poly(ADP-ribose) polymerase biomarker assay for clinical trials of PARP inhibitors.
Topics: Animals; Antineoplastic Agents; Benzimidazoles; Biomarkers; Clinical Trials as Topic; Dacarbazine; Disease Models, Animal; Enzyme Inhibitors; Enzyme-Linked Immunosorbent Assay; Female; Humans; Melanoma, Experimental; Mice; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Temozolomide | 2008 |
Potentiation of temozolomide cytotoxicity by poly(ADP)ribose polymerase inhibitor ABT-888 requires a conversion of single-stranded DNA damages to double-stranded DNA breaks.
Topics: Animals; Antineoplastic Agents; Benzimidazoles; Cell Death; Cell Line, Tumor; Dacarbazine; Disease Models, Animal; DNA Breaks, Double-Stranded; DNA Breaks, Single-Stranded; DNA Repair; DNA Replication; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Mice; Poly(ADP-ribose) Polymerase Inhibitors; Rats; Temozolomide | 2008 |
Effective sensitization of temozolomide by ABT-888 is lost with development of temozolomide resistance in glioblastoma xenograft lines.
Topics: Animals; Benzimidazoles; Cell Line, Tumor; Dacarbazine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Glioblastoma; Humans; Mice; Mice, Nude; Poly(ADP-ribose) Polymerases; Temozolomide; Xenograft Model Antitumor Assays | 2009 |
Poly(ADP-ribose) polymerase inhibitor ABT-888 potentiates the cytotoxic activity of temozolomide in leukemia cells: influence of mismatch repair status and O6-methylguanine-DNA methyltransferase activity.
Topics: Antineoplastic Agents, Alkylating; Benzimidazoles; Cell Line, Tumor; Dacarbazine; DNA Mismatch Repair; Drug Synergism; Enzyme Inhibitors; Humans; Leukemia; O(6)-Methylguanine-DNA Methyltransferase; Poly(ADP-ribose) Polymerase Inhibitors; Temozolomide | 2009 |
Acquired resistance to combination treatment with temozolomide and ABT-888 is mediated by both base excision repair and homologous recombination DNA repair pathways.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzimidazoles; Cell Line, Tumor; Cell Proliferation; Dacarbazine; DNA Repair; Down-Regulation; Drug Resistance, Neoplasm; Histones; Humans; Phosphorylation; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Rad51 Recombinase; Recombination, Genetic; RNA, Small Interfering; Sequence Homology; Temozolomide | 2009 |
ABT-888 confers broad in vivo activity in combination with temozolomide in diverse tumors.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Dacarbazine; DNA Damage; DNA Modification Methylases; DNA Repair; DNA Repair Enzymes; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Humans; Mice; Mice, SCID; Neoplasm Metastasis; Neoplasm Transplantation; Temozolomide; Tumor Suppressor Proteins | 2009 |
PTEN loss compromises homologous recombination repair in astrocytes: implications for glioblastoma therapy with temozolomide or poly(ADP-ribose) polymerase inhibitors.
Topics: Animals; Antineoplastic Agents, Alkylating; Astrocytes; Benzimidazoles; Brain Neoplasms; Cyclin-Dependent Kinase Inhibitor p16; Dacarbazine; DNA Damage; DNA Repair; Glioblastoma; Methylnitronitrosoguanidine; Mice; Mice, Transgenic; Poly(ADP-ribose) Polymerase Inhibitors; PTEN Phosphohydrolase; Recombination, Genetic; Temozolomide | 2010 |
Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitor.
Topics: Animals; Antineoplastic Agents; Benzamides; Benzimidazoles; BRCA2 Protein; Cell Line, Tumor; Cysteine; Dacarbazine; DNA Repair; Drug Synergism; Female; Humans; Mice; Mice, Inbred C57BL; Mice, SCID; Neoplasms, Experimental; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Temozolomide; Xenograft Model Antitumor Assays | 2012 |
[Analysis of the relevant factors of mechanism for telozolomide chemoresistance].
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Benzimidazoles; Dacarbazine; DNA Repair; Drug Resistance, Neoplasm; Humans; Membrane Proteins; O(6)-Methylguanine-DNA Methyltransferase; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins; Purines; Pyrimidines; Temozolomide; Tumor Suppressor Protein p53 | 2011 |
Evaluation of poly (ADP-ribose) polymerase inhibitor ABT-888 combined with radiotherapy and temozolomide in glioblastoma.
Topics: Antineoplastic Agents; Benzimidazoles; Blotting, Western; Cell Line, Tumor; Cell Survival; Chemoradiotherapy; Dacarbazine; Enzyme Inhibitors; Fluorescent Antibody Technique; Glioblastoma; Humans; Poly(ADP-ribose) Polymerases; Temozolomide | 2013 |
ABCB1, ABCG2, and PTEN determine the response of glioblastoma to temozolomide and ABT-888 therapy.
Topics: Acridines; Animals; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzimidazoles; Blood-Brain Barrier; Blotting, Western; Brain; Cell Line, Tumor; Dacarbazine; Dogs; Glioblastoma; Humans; Immunohistochemistry; Kaplan-Meier Estimate; LLC-PK1 Cells; Madin Darby Canine Kidney Cells; Metabolic Clearance Rate; Mice, Knockout; Mice, Nude; PTEN Phosphohydrolase; Swine; Temozolomide; Tetrahydroisoquinolines; Treatment Outcome | 2014 |
Rationale for poly(ADP-ribose) polymerase (PARP) inhibitors in combination therapy with camptothecins or temozolomide based on PARP trapping versus catalytic inhibition.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Camptothecin; Cell Cycle; Cell Line, Tumor; Cell Survival; Chickens; Dacarbazine; DNA Damage; DNA Repair; Drug Synergism; Enzyme Inhibitors; Humans; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Temozolomide | 2014 |
Synergistic cytotoxicity of the poly (ADP-ribose) polymerase inhibitor ABT-888 and temozolomide in dual-drug targeted magnetic nanoparticles.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzimidazoles; Carcinoma, Hepatocellular; Chemistry, Pharmaceutical; Dacarbazine; DNA Damage; Dose-Response Relationship, Drug; Drug Carriers; Drug Combinations; Drug Synergism; G2 Phase Cell Cycle Checkpoints; Hep G2 Cells; Humans; Liver Neoplasms; Magnetite Nanoparticles; Membrane Potential, Mitochondrial; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Signal Transduction; Technology, Pharmaceutical; Temozolomide | 2015 |
Discordant in vitro and in vivo chemopotentiating effects of the PARP inhibitor veliparib in temozolomide-sensitive versus -resistant glioblastoma multiforme xenografts.
Topics: Animals; Antineoplastic Agents, Alkylating; Benzimidazoles; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA Damage; Drug Resistance, Neoplasm; Gene Knockdown Techniques; Glioblastoma; Humans; Mice, Nude; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Temozolomide; Xenograft Model Antitumor Assays | 2014 |
Targeting the DNA repair pathway in Ewing sarcoma.
Topics: Animals; Benzimidazoles; Camptothecin; Cell Death; Cell Line, Tumor; Dacarbazine; DNA Breaks, Double-Stranded; DNA Repair; Drug Synergism; Enzyme Inhibitors; Irinotecan; Mice, Nude; Molecular Targeted Therapy; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Sarcoma, Ewing; Temozolomide; Xenograft Model Antitumor Assays | 2014 |
ABT-888 enhances cytotoxic effects of temozolomide independent of MGMT status in serum free cultured glioma cells.
Topics: Apoptosis; Autophagy; Benzimidazoles; Brain Neoplasms; Culture Media, Serum-Free; Dacarbazine; DNA Breaks, Double-Stranded; DNA Modification Methylases; DNA Repair Enzymes; Glioma; Humans; Neoplastic Stem Cells; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Temozolomide; Tumor Cells, Cultured; Tumor Suppressor Proteins | 2015 |
Delineation of MGMT Hypermethylation as a Biomarker for Veliparib-Mediated Temozolomide-Sensitizing Therapy of Glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Cell Line, Tumor; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Mice; Mice, Nude; Poly(ADP-ribose) Polymerase Inhibitors; Polymerase Chain Reaction; Random Allocation; Temozolomide; Tumor Suppressor Proteins; Up-Regulation; Xenograft Model Antitumor Assays | 2016 |
Evaluation of Concurrent Radiation, Temozolomide and ABT-888 Treatment Followed by Maintenance Therapy with Temozolomide and ABT-888 in a Genetically Engineered Glioblastoma Mouse Model.
Topics: Animals; Apoptosis; Benzimidazoles; Cell Line, Tumor; Chemoradiotherapy; Dacarbazine; Disease Models, Animal; Drug Resistance, Neoplasm; Genetic Engineering; Glioblastoma; Humans; Magnetic Resonance Imaging; Mice; Poly(ADP-ribose) Polymerase Inhibitors; Temozolomide | 2016 |
PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Cell Line, Tumor; Cisplatin; Dacarbazine; Drug Synergism; Etoposide; Gene Expression Regulation, Neoplastic; Genomics; Humans; Indoles; Mice; Nuclear Proteins; Phthalazines; Piperazines; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Small Cell Lung Carcinoma; Temozolomide; Xenograft Model Antitumor Assays | 2017 |
Inhibited, trapped or adducted: the optimal selective synthetic lethal mix for BRCAness.
Topics: Benzimidazoles; Breast Neoplasms; Carboplatin; Humans; Neoplasm Recurrence, Local; Paclitaxel; Temozolomide | 2018 |
SLFN11: a new synthetic lethal target?
Topics: Benzimidazoles; Double-Blind Method; Humans; Lung Neoplasms; Nuclear Proteins; Small Cell Lung Carcinoma; Temozolomide | 2018 |
ABT-888 restores sensitivity in temozolomide resistant glioma cells and xenografts.
Topics: Animals; Benzimidazoles; Cell Line, Tumor; DNA-Binding Proteins; Drug Resistance, Neoplasm; Female; Gene Knockdown Techniques; Glioma; Humans; Mice; Neoplasm Grading; RNA, Small Interfering; Temozolomide; Xenograft Model Antitumor Assays | 2018 |
Is SLFN11 a Promising Predictive Biomarker of Poly (ADP-ribose) Polymerase Inhibitor Sensitivity in Small-Cell Lung Cancer? Not Yet!
Topics: Adenosine Diphosphate; Benzimidazoles; Biomarkers; Double-Blind Method; Humans; Lung Neoplasms; Nuclear Proteins; Ribose; Temozolomide | 2019 |
Reply to F. Liang.
Topics: Benzimidazoles; Double-Blind Method; Humans; Lung Neoplasms; Temozolomide | 2019 |
Tooth Formation as Experimental Model to Study Chemotherapy on Tissue Development: Effect of a Specific Dose of Temozolomide/Veliparib.
Topics: Animals; Benzimidazoles; Claudin-1; Mice; Models, Theoretical; Odontogenesis; Temozolomide | 2022 |